Georgia is currently home to 1949 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Atlanta, Augusta, Decatur and Savannah. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Investigate the Safety and Efficacy of TMP-301 Compared to Placebo in Adult Patients With Alcohol Use Disorder
NCT06648655
Recruiting
TMP-301 has been shown in preclinical models to reduce consumption of alcohol and other addictive substances. It has been tested in healthy subjects and has been found to be safe and tolerated at doses predicted to be efficacious in alcohol use disorder. This study is being conducted to evaluate the safety, tolerability and efficacy of TMP-301 in patients with alcohol use disorder.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/08/2025
Locations: CenExcel iResearch, Decatur, Georgia
Conditions: Alcohol Use Disorder (AUD)
Register for Updates
A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine
NCT06615375
Recruiting
In this challenge study, the bioconjugate candidate vaccine Shigella4V2 will be tested for its ability to induce an immune response that protects healthy adult volunteers from infection with a wild-type Shigella sonnei strain compared to participants receiving placebo.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
07/08/2025
Locations: Hope Clinic of Emory University, Atlanta, Georgia
Conditions: Shigellosis
Register for Updates
A Phase 1 Open-Label Study of the Safety of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) in Young Adult (1A) and Pediatric (1B) Patients With Dilated Cardiomyopathy (DCM)
NCT06464588
Recruiting
This is a Phase 1 study to determine the safety and efficacy of allogeneic neonatal mesenchymal stromal cells (nMSCs) for the treatment of Dilated Cardiomyopathy. The purpose of the study is to help doctors and scientists learn if allogeneic neonatal mesenchymal stromal cells (nMSCs) infusions are a safe and effective way to improve cardiac function and left ventricular ejection fraction.
Gender:
ALL
Ages:
Between 4 years and 30 years
Trial Updated:
07/08/2025
Locations: Hughes Spalding Children's Hospital, Atlanta, Georgia
Conditions: Dilated Cardiomyopathy
Register for Updates
Safety and Efficacy of Workflows of High Volume Single Operators in a LAAO Device Implant Procedural Day
NCT06436924
Recruiting
SAFE HV is an observational, prospective, multi-center, non-randomized study evaluating real-world clinical experience of centers where a single procedural physician schedules eight or more left atrial appendage occlusion (LAAO) device implant procedures in a single calendar day.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Memorial Health University Medical Center, Savannah, Georgia
Conditions: Atrial Fibrillation
Register for Updates
A Study of Pitolisant in Patients With Prader-Willi Syndrome
NCT06366464
Recruiting
This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, global clinical study to assess the efficacy and safety of pitolisant in patients living with Prader-Willi syndrome. The primary objective of this study is to evaluate the efficacy of pitolisant in treating excessive daytime sleepiness (EDS) in patients ≥6 years of age with Prader-Willi syndrome. Secondary objectives include assessing the impact of pitolisant on: Irritable and disruptive behaviors Hyperphagia Other... Read More
Gender:
ALL
Ages:
6 years and above
Trial Updated:
07/08/2025
Locations: Atlanta Diabetes Associates, Atlanta, Georgia
Conditions: Prader-Willi Syndrome
Register for Updates
The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO System Use in Conjunction With VISITAG SURPOINT Module for the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation.
NCT06324201
Recruiting
Observational, multi-center, non-randomized, post-market study. This is a nested sub-study of the REAL AF Registry. Consecutive symptomatic drug refractory paroxysmal atrial fibrillation (PAF) patients from the registry will be screened for enrollment to this sub-study per inclusion and exclusion criteria.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Piedmont Healthcare, Atlanta, Georgia
Conditions: Paroxysmal Atrial Fibrillation
Register for Updates
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
NCT05208190
Recruiting
Two-hundred and eighty individuals with schizophrenia who have a recent history of violent acts will be randomized in this 2-arm, parallel-group, 24-week, open-label, 7-site clinical trial to examine the effects of treatment with clozapine vs antipsychotic treatment as usual (TAU) for reducing the risk of violent acts in real-world settings
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/08/2025
Locations: Augusta University Research Institute, Inc., Augusta, Georgia
Conditions: Schizophrenia, Schizoaffective Disorder
Register for Updates
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
NCT04889872
Recruiting
This study objective is to establish the safety and effectiveness of the Edwards SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve systems in subjects with moderate, calcific aortic stenosis. Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/08/2025
Locations: Emory University Atlanta, Atlanta, Georgia
Conditions: Aortic Stenosis, Calcific, Aortic Valve Stenosis
Register for Updates
Connect for Cancer Prevention Study (Connect)
NCT04609072
Recruiting
Background: The National Cancer Institute, part of the National Institutes of Health, has partnered with nine health care systems across the U.S. to establish the Connect for Cancer Prevention Study. While researchers have made important discoveries, there is more to learn to lower the number of people affected by cancer. By taking part in Connect, participants can help researchers learn how the way we live, our genetics, and our health history may affect cancer risk. Objective: To study and... Read More
Gender:
ALL
Ages:
Between 30 years and 70 years
Trial Updated:
07/08/2025
Locations: Kaiser Permanente Georgia, Atlanta, Georgia
Conditions: Cancer, General Research Use
Register for Updates
FUVID Study: Functional Characterization of Children With Chronic Venous Thromboembolic Disease
NCT04583878
Recruiting
This is a multi-center prospective cohort study of patients with first-episode deep venous thrombosis and pulmonary embolism.
Gender:
ALL
Ages:
Between 8 years and 21 years
Trial Updated:
07/08/2025
Locations: Emory University / Children's Heathcare Atlanta, Atlanta, Georgia
Conditions: Deep Venous Thrombosis, Pulmonary Embolism
Register for Updates
PARADIGM: Amplatzer Valvular Plug for PVL Closure
NCT04489823
Recruiting
The Paradigm study is a prospective, multicenter, single arm study to demonstrate the safety and effectiveness of the Amplatzer Valvular Plug III (AVP III) as a treatment for clinically significant PVLs following surgical implant of a mechanical or biological heart valve implanted in the aortic or mitral position.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Emory University Hospital, Atlanta, Georgia
Conditions: Paravalvular Aortic Regurgitation
Register for Updates
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
NCT04363684
Recruiting
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Emory University, Atlanta, Georgia
Conditions: Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis, Oligosymptomatic PSP (oPSP), C9orf72, GRN Related Frontotemporal Dementia, MAPT Gene Mutation, TBK1 Gene Mutation, Oligosymptomatic Progressive Supranuclear Palsy
Register for Updates